cisplatin + carboplatin + nedaplatin

This combination refers to a group of platinum-based antineoplastic agents—cisplatin, carboplatin, and nedaplatin—that are frequently utilized in the treatment of advanced or recurrent metastatic esophageal squamous cell carcinoma (ESCC). These agents function as DNA alkylating-like compounds that induce intra-strand and inter-strand DNA cross-links, thereby inhibiting DNA synthesis and transcription, which ultimately triggers cellular apoptosis. In clinical trials, such as those sponsored by Fujian Provincial Cancer Hospital (e.g., NCT05146323), these platinum drugs are often used as the platinum backbone in combination with other agents like paclitaxel and immune checkpoint inhibitors like tislelizumab. While they share a common mechanism of action, they are selected based on their distinct toxicity profiles; for instance, carboplatin and nedaplatin are often preferred over cisplatin in elderly patients due to reduced nephrotoxicity and neurotoxicity.

Brand names

Aqupla

Other names

cis-diamminedichloroplatinum(II)cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cis-Diammine(glycolato)platinumnaidaplatinnideplatin